Lexicon Pharmaceuticals (LXRX)
continues to generate data on its SGLT-1/2 inhibitor LX4211 that
suggest this is an effective and promising medication for treating not
only Type 2 diabetes (the common target for non-insulin medications for
diabetes), but also Type 1 as well. Lexicon's most recent update, a
small short-term Phase II study in Type 1 diabetics is certainly a
positive update, but it's not what investors really want to see. Lexicon
still needs to find a development partner for LX4211 and the ongoing
delays don't help sentiment or the long-term prospects for the drug.
Read the full article here:
More Positive News For Lexicon, But Not The Big Announcement
No comments:
Post a Comment